Sulfathiazole-d₄ 

Sulfathiazole-d₄ is a deuterium labeled Sulfathiazole. Sulfathiazole is an orally active, endocrine disruptor targeting the steroidogenic pathway, specifically enhancing the activity of CYP19 in human adrenal cancer cells (H295R) and upregulating the mRN expression of CYP17, CYP19, and 3β-HSD. Sulfathiazole increases the production of 17-estradiol (E2) and has endocrine disrupting effects on aquatic organisms such as the Japanese medaka fish^[1][2][3][4].

259.34

C₉H₅D₄N₃O₂S₂

1020719-89-4

72-14-0

Solid

White to off-white

O=S(C1=C([2H])C([2H])=C(N)C([2H])=C1[2H])(NC2=NC=CS2)=O

Room temperature in continental US; may vary elsewhere.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-236.  [Content Brief]

  [2]. Ji K, Choi K, Lee S, Park S, Khim JS, Jo EH, Choi K, Zhang X, Giesy JP. Effects of sulfathiazole, oxytetracycline and chlortetracycline on steroidogenesis in the human adrenocarcinoma (H295R) cell line and freshwater fish Oryzias latipes. J Hazard Mater. 2010 Oct 15;182(1-3):494-502.  [Content Brief]

  [3]. Endicott, et al. Lesions in rats given sulfathiazole, sulfadiazine, sulfanilamide, sulfamerazine, sulfapyrazine, or acetylsulfadiazine in purified diets. Public Health Reports (1896-1970) (1944): 49-54.

  [4]. Zor, et al. Sulfathiazole as potential corrosion inhibitor for copper in 0.1 M NaCl. Protection of Metals and Physical Chemistry of Surfaces 50 (2014): 530-537.